The partnership intends to make the DiviTum TKa test accessible to the more than 8,000 people in Spain and Portugal who are diagnosed with metastatic breast cancer annually
Biovica and Palex Group sign agreement for cancer test. (Credit: Ahmad Ardity from Pixabay)
Cancer monitoring company Biovica has entered a collaboration agreement with the Palex Group to distribute DiviTum TKa cancer test in Spain and Portugal.
Palex Group is a hospital equipment supplier with a history of marketing oncology tests and surgical instruments in southern Europe.
The partnership intends to make the test accessible to the more than 8,000 people in Spain and Portugal who are diagnosed with metastatic breast cancer annually.
Palex will lead the test’s introduction and adoption, concentrating on raising awareness and knowledge among breast oncologists and other relevant decision-makers.
The hospital equipment supplier will integrate the test into clinical guidelines using DiviTum TKa’s value for both patients and professionals.
Palex Group CEO Xavier Carbonell said: “Our commitment to DiviTum TKa reflects our strong determination to provide health professionals and their patients with disruptive solutions capable of improving people’s lives.
“In this case, with a non-invasive solution that allows prognosis and monitoring the effectiveness of treatment for advanced cancer patients treated with CDK4/6 inhibitors.”
Biovica is engaged in the development and marketing of blood-based biomarker assays to assist oncologists in tracking the progression of cancer. The company works with global pharmaceutical firms and oncology centres.
DiviTum TKa measures cell proliferation by finding the TKa biomarker in the blood.
According to the cancer monitoring company, the assay has shown its ability to offer insight into therapy effectiveness in several clinical studies.
The first use for the DiviTum TKa test is treatment monitoring of metastatic breast cancer patients.
DiviTum TKa is CE-marked in the European Union and has US Food and Drug Administration (FDA) 510(k) clearance in the US.
Biovica commercialisation vice president Helle Fisker said: “Palex Group has a proven track record in marketing precision medicine solutions for breast cancer, with impressive commercial results.
“We are delighted to sign an agreement with such a successful and dynamic team. This agreement establishes a strategic commercial approach for DiviTum TKa in the Spanish and Portuguese markets.”